Diagnosis of latent polycythemia vera: A clinician’s opinion

Diagnosis of latent polycythemia vera: A clinician’s opinion

Aim. To identify the clinical features of latent polycythemia vera (PV) as an independent nosological entity. Subjects and methods. The investigation enrolled 81 patients (50 with extensive (manifest) PV and 31 with latent PV) who had visited the Outpatient Department, Hematology Research Center, Mi...

Full description

Bibliographic Details
Main Authors:	A L Melikian, I N Subortseva, A M Kovrigina, T I Kolosheynova, A O Abdullaev, P I Kuznetsova, A B Sudarikov, S M Kulikov
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2016-07-01
Series:	Терапевтический архив
Subjects:	polycythemia vera jak2 v617f latent/masked polycythemia thromboses jak2v617f
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/31985/pdf_1

Similar Items

JAK2 Negative Polycythemia Vera
by: Geetha J P., et al.
Published: (2010-07-01)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)

Transient Spinal Cord Ischemia as Presenting Manifestation of Polycythemia Vera
by: Sónia Costa, et al.
Published: (2011-10-01)

Eryptosis in polycythemia vera and essential thrombocythemia*
by: Paweł Kopka, et al.
Published: (2020-04-01)

Impact of Anti-Endothelial Cell Antibodies (AECAs) in Patients with Polycythemia Vera and Thrombosis
by: Cacciola, E., et al.
Published: (2022)

POLYCYTHEMIA VERA IDENTIFIED IN A PATIENT WITH RESTENOSIS OF THE SUPERFICIAL FEMORAL ARTERY. CLINICAL CASE AND REVIEW OF THE LITERATURE
by: G. Sh. Safuanova, et al.
Published: (2017-05-01)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)

Recurrent cerebral venous sinus thrombosis in a young man- A case report of JAK2-negative polycythemia vera
by: Akanksha Singh, et al.
Published: (2019-01-01)

Policitemia Vera en la era del Jak: breve análisis del diagnóstico después de su introducción
by: Norma Fernández Delgado, et al.

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey
by: Rafet Eren, et al.
Published: (2020-10-01)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
by: M.E. Bjørn, et al.
Published: (2014-01-01)

Introducción del estudio molecular de la mutación JAK2V617F en neoplasias mieloproliferativas clásicas BCR-ABL negativas
by: Ana María Amor-Vigil, et al.

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019-01-01)

Quantitative analysis of the erythrocyte membrane proteins in polycythemia vera patients treated with hydroxycarbamide
by: Darshana Kottahachchi, et al.
Published: (2015-06-01)

All we know about polycythemia vera: literature review and own experience
by: K. M. Abdulkadyrov, et al.
Published: (2015-10-01)

Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit
by: Haythem A. AL-Rubaie, et al.
Published: (2015-01-01)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
by: Rasmus K. Pedersen, et al.
Published: (2020-03-01)

Medical image of the week: portal vein thrombosis in a patient with polycythemia vera
by: Babary H, et al.
Published: (2017-08-01)

Cluster-Like Headache Revealing Polycythemia Vera: A Case Report
by: Cyprian Popescu
Published: (2020-06-01)

Experience in treating portal thromboses in patients with chronic myeloproliferative diseases
by: A L Melikyan, et al.
Published: (2016-01-01)

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis
by: Ralfs Buks, et al.
Published: (2021-03-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
by: Claudia Schubert, et al.
Published: (2019-04-01)

Anticoagulation for Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: The Drug and the Duration
by: Wafik G. Sedhom, et al.
Published: (2021-05-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit)
by: Zito Luca, et al.
Published: (2011-08-01)

Can pegylated interferon improve the outcome of polycythemia vera patients?
by: Elena Crisà, et al.
Published: (2017-01-01)

Polycythemia Vera: New Diagnostic Concept and Its Types
by: AM Kovrigina, et al.
Published: (2016-04-01)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
by: Jerry L. Spivak, et al.
Published: (2021-03-01)

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016
by: Pedrazzani, Fabiane Spagnol
Published: (2017)

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016
by: Pedrazzani, Fabiane Spagnol
Published: (2017)

Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016
by: Pedrazzani, Fabiane Spagnol
Published: (2017)

Diagnosis of exon 12‐positive polycythemia vera rescued by NGS
by: Antoine Geay, et al.
Published: (2020-05-01)

Anomalies érythroïdes et endothéliales dans la Polyglobulie de Vaquez : rôle de la mutation JAK2V617F et des traitements par hydroxycarbamide et interféron-alpha
by: Brusson, Mégane
Published: (2017)

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases
by: A L MELIKYAN, et al.
Published: (2018-07-01)

Polycythemia vera: Correlation of JAK2V617F mutation with clinicohematologic characteristics. A single centre experience.
by: Deepti Mutreja, et al.
Published: (2014-08-01)

When hemolysis masks polycythemia vera
by: Coralie Derrieux, et al.
Published: (2019-03-01)

Low <i>Jak2</i> V617f Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional <i>Calr</i> or <i>Mpl</i> Gene Mutations
by: Tatiana V. Makarik, et al.
Published: (2021-04-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)